-
公开(公告)号：US20220220220A1
公开(公告)日：2022-07-14
申请号：US17570649
申请日：2022-01-07
发明人： Joseph M. Luettgen , Lumelle Schneeweis , Ginger Chao Rakestraw , Christina Terragni , Andrew Karl Dilger , Jason Robert Pinckney , Steven Sheriff , Kevin Kish , Yongmi An , William R. Ewing , Stanley Richard Krystek, JR. , Aaron Paul Yamniuk
摘要： The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.
-
公开(公告)号：US12065505B2
公开(公告)日：2024-08-20
申请号：US17570649
申请日：2022-01-07
发明人： Joseph M. Luettgen , Lumelle Schneeweis , Ginger Chao Rakestraw , Christina Terragni , Andrew Karl Dilger , Jason Robert Pinckney , Steven Sheriff , Kevin Kish , Yongmi An , William R. Ewing , Stanley Richard Krystek, Jr. , Aaron Paul Yamniuk
CPC分类号： C07K16/36 , A61P7/04 , C07K16/44 , G01N33/86 , G01N33/94 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/92
摘要： The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.
-
公开(公告)号：US10556948B2
公开(公告)日：2020-02-11
申请号：US15364612
申请日：2016-11-30
发明人： Mohan Srinivasan , Shrikant Deshpande , Qihong Zhao , Huadong Sun , Ginger Rakestraw , Guodong Chen , Richard Y. Huang , Steven Sheriff , Cristian Rodriguez , John P. Throup , Rose A. Dibella
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
-
4.发明授权公开(公告)号：US11136406B2
公开(公告)日：2021-10-05
申请号：US16723047
申请日：2019-12-20
发明人： Anish Suri , Steven Sheriff , Suzanne Suchard , Aaron Yamniuk , Stanley Krystek , James Tamura , James Bryson , Steven Grant , Philip Drew
IPC分类号： A61K39/395 , C07K16/28 , A61K45/06 , C07K16/18 , A61K39/00
摘要： Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
-
公开(公告)号：US10544228B2
公开(公告)日：2020-01-28
申请号：US15259828
申请日：2016-09-08
发明人： Anish Suri , Steven Sheriff , Suzanne Suchard , Aaron Yamniuk , Stanley Krystek , James Tamura , James Bryson , Steven Grant , Philip Drew
摘要： Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
-
公开(公告)号：US11708405B2
公开(公告)日：2023-07-25
申请号：US16728757
申请日：2019-12-27
发明人： Mohan Srinivasan , Shrikant Deshpande , Qihong Zhao , Huadong Sun , Ginger Rakestraw , Guodong Chen , Richard Y. Huang , Steven Sheriff , Cristian Rodriguez , John P. Throup , Rose A. Dibella
CPC分类号： C07K16/24 , A61K9/0019 , A61K47/6845 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
-
公开(公告)号：US20150086552A1
公开(公告)日：2015-03-26
申请号：US14402322
申请日：2013-05-21
发明人： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty , Milan Gao , Steven Sheriff , Noah Ditto , Nels B. Hamacher
IPC分类号： C07K16/24
CPC分类号： C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
摘要翻译： 本发明涉及使用包含与IL-17A和IL-17F交叉反应的结合实体的双特异性抗体和结合IL-23p19的结合实体来拮抗IL-17A，IL-17F和IL-23的活性 。 本发明涉及新的双特异性抗体形式及其使用方法。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.027 秒)
